Lupin Faces 6 FDA Observations at Nagpur Injectable Facility

Lupin Limited’s Nagpur injectables facility has received six observations following a U.S. FDA inspection conducted from September 8–16, 2025. The company has acknowledged the findings and plans to respond within the stipulated timeframe. While details of the observations remain undisclosed, they pertain to manufacturing and quality control practices. MD Nilesh Gupta reaffirmed Lupin’s commitment to CGMP compliance across all facilities. The inspection is part of routine FDA oversight for plants supplying the U.S. market. The outcome could impact regulatory clearances and investor sentiment, though no immediate restrictions have been reported. Lupin’s prompt disclosure reflects transparency. How swiftly it resolves the issues will be key to maintaining its global reputation and regulatory standing.